Thomas K. Karikari

Dec 23, 2024 | alzres.biomedcentral.com | Georgette Argiris |Muge Akinci |Cleofé Peña-Gómez |Eleni Palpatzis |Marina García-Prat |Mahnaz Shekari | +8 more

ReferencesJack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. Article  PubMed  Google Scholar  Milà-Alomà M, Suárez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Ther Adv Neurol Disord. 2019;18(12):1756286419888819.

Oct 25, 2024 | journals.sagepub.com | Julia Gundersen |Fernando Gonzalez-Ortiz |Thomas K. Karikari |Bjørn-Eivind Kirsebom

Introduction Acute ischemic stroke (AIS), a leading cause of mortality and long-term disability, poses an enormous global burden.1,2 Thrombolysis and thrombectomy are highly effective but time-sensitive treatments that improve long-term outcome after AIS.3 Approximately 25% of patients presenting with AIS have a non-ischemic neurological or non-neurological condition, such as peripheral vestibular dysfunction (23.2%), seizures (13.0%) functional disorders (9.7%) and migraine (7.8%).4...

May 3, 2024 | nature.com | Gleb Bezgin |Thomas K. Karikari |Henrik Zetterberg |Kaj Blennow |Pedro Rosa-Neto

AbstractNeuronal dysfunction and cognitive deterioration in Alzheimer’s disease (AD) are likely caused by multiple pathophysiological factors. However, mechanistic evidence in humans remains scarce, requiring improved non-invasive techniques and integrative models.

Apr 4, 2024 | nature.com | Fernando Gonzalez-Ortiz |Jose Celso Contador |Geir Bråthen |Przemyslaw R. Kac |Johanna Nilsson |Kathleen Hayden | +5 more

AbstractStaging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration could identify individuals at risk for cognitive decline in Alzheimer’s disease (AD). In blood, phosphorylated tau (p-tau) associates with Aβ pathophysiology but an AD-type neurodegeneration biomarker has been lacking.

Apr 4, 2024 | nature.com | Fernando Gonzalez-Ortiz |Jose Celso Contador |Geir Bråthen |Przemyslaw R. Kac |Johanna Nilsson |Kathleen Hayden | +5 more

AbstractStaging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration could identify individuals at risk for cognitive decline in Alzheimer’s disease (AD). In blood, phosphorylated tau (p-tau) associates with Aβ pathophysiology but an AD-type neurodegeneration biomarker has been lacking.